Great Basin Scientific Inc (NASDAQ:GBSN), Inc. has confirmed the commencement of a clinical trial for its Stool Bacterial Pathogens Panel. The molecular diagnostics company will put its focus on the multi-plex molecular assay detecting common bacterial agents the likes of foodborne pathogens. Nucleic acids of Salmonella, E.coli, Shigella and Campylobacter will be the panel’s key target.
Being the second start of the five aligned clinical trials for this year, the company has expressed its excitement and optimism that the results will be of great value to its customers.
The results will also play a role in demonstrating the company’s uniqueness, resourcefulness, and grip of the market.
Speaking about the Company’s accomplishment Ryan Ashton, co-founder and Chief Executive Officer of Great Basin Scientific expressed the company’s confidence in being able to embrace its development plans to fruition. Ashton went ahead to describe the commitment, organization and talent within the company’s R&D group all which are of importance in the achievement of its goals.
The company stands a better chance to meet its vision of making molecular diagnostic testing so simple and cost-effective. It is dedicated to developing to use any simple but powerful technology to get sample-to-result products. These products are expected to satisfy the testing of every patient for severe infection, reduce misdiagnoses as well as diminish the spread of infectious disease.
But as all this unfolds, something else is happening behind the scenes in the stock market. As a result of heavy trading, the company’s shares rose by 4.3% to trade at $1.70. Within a very short time, more than 5.03 million shares of Great Basin have changed hands. The amount was over and above the projected 30-day volume of 1.2 million shares per day.
Clearly, Great Basin is not anywhere near to relent. In fact, there are all signs that the company is gearing for more development, given the expected success of the most current. Let’s all be on the look out to see what more the company has to offer.
